Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non Hodgkin's Lymphoma Refractory/Relapsed”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableNo Longer AvailableNCT04757259
What this trial is testing

Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib

Who this might be right for
Relapsed/Refractory Chronic Lymphocytic LeukemiaNon-hodgkin's Lymphoma
Alexion Pharmaceuticals, Inc.
Testing effectiveness (Phase 2)Study completedNCT00093769
What this trial is testing

Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Jonsson Comprehensive Cancer Center 15
Early research (Phase 1)Study completedNCT00042900
What this trial is testing

Pyroxamide in Treating Patients With Advanced Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+5 more
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Looking for participantsNCT06395870
What this trial is testing

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
B-Cell Non-Hodgkin Lymphoma-RecurrentB-Cell Non-Hodgkin Lymphoma-Refractory
Tianjin Medical University Cancer Institute and Hospital 33
Testing effectiveness (Phase 2)Study completedNCT00077194
What this trial is testing

FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
National Cancer Institute (NCI) 35
Early research (Phase 1)Active Not RecruitingNCT01955499
What this trial is testing

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Lymphoplasmacytic Lymphoma+7 more
National Cancer Institute (NCI) 39
Early research (Phase 1)Study completedNCT00697684
What this trial is testing

Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Lymphocytic Leukemia+4 more
Beth Israel Deaconess Medical Center 29
Early research (Phase 1)Ended earlyNCT00860171
What this trial is testing

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Hodgkin LymphomaRecurrent T-Cell Non-Hodgkin Lymphoma+3 more
Fred Hutchinson Cancer Center 16
Testing effectiveness (Phase 2)Looking for participantsNCT06066203
What this trial is testing

GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies

Who this might be right for
Non-hodgkin's Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd. 40
Testing effectiveness (Phase 2)WithdrawnNCT02623920
What this trial is testing

Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaMediastinal Large B-cell LymphomaGrey Zone Lymphoma+4 more
University of Arizona
Testing effectiveness (Phase 2)Study completedNCT02611323
What this trial is testing

Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Non-Hodgkin's Lymphoma
Hoffmann-La Roche 133
Very early researchNot Yet RecruitingNCT06879262
What this trial is testing

Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL

Who this might be right for
R/R NHL
Tongji Hospital 60
Early research (Phase 1)Ended earlyNCT01643603
What this trial is testing

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Who this might be right for
Non-Hodgkin's LymphomaHodgkin's LymphomaMyeloid Leukemia+3 more
Barbara Ann Karmanos Cancer Institute 5
Early research (Phase 1)Study completedNCT03467373
What this trial is testing

Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Who this might be right for
B-Cell LymphomaNon-Hodgkin Lymphoma
Hoffmann-La Roche 111
Testing effectiveness (Phase 2)Study completedNCT05371054
What this trial is testing

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Who this might be right for
LymphomaNon-Hodgkin LymphomaNHL+2 more
National Cancer Institute (NCI) 8
Early research (Phase 1)Looking for participantsNCT07082803
What this trial is testing

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

Who this might be right for
LymphomaLymphoma, Non Hodgkin
Treeline Biosciences, Inc. 180
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07771361
What this trial is testing

BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma

Who this might be right for
Non-Hodgkin Lymphoma Refractory/ RelapsedMultiple Myeloma RefractoryMultiple Myeloma in Relapse+5 more
Luminary Therapeutics 90
Testing effectiveness (Phase 2)Ended earlyNCT03379051
What this trial is testing

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

Who this might be right for
Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma
TG Therapeutics, Inc. 78
Testing effectiveness (Phase 2)Looking for participantsNCT02259556
What this trial is testing

CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas

Who this might be right for
Hodgkin's LymphomaNon-Hodgkin's Lymphoma
Chinese PLA General Hospital 30
Testing effectiveness (Phase 2)Study completedNCT00737529
What this trial is testing

Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Who this might be right for
Mantle Cell Lymphoma
Celgene 134
Next Page